JP2017525737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525737A5 JP2017525737A5 JP2017512046A JP2017512046A JP2017525737A5 JP 2017525737 A5 JP2017525737 A5 JP 2017525737A5 JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017525737 A5 JP2017525737 A5 JP 2017525737A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- substituted
- cycloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 40
- 125000001072 heteroaryl group Chemical group 0.000 claims 39
- 125000000623 heterocyclic group Chemical group 0.000 claims 38
- -1 hydrate Substances 0.000 claims 34
- 125000003118 aryl group Chemical group 0.000 claims 30
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000003277 amino group Chemical group 0.000 claims 13
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 13
- 125000003386 piperidinyl group Chemical group 0.000 claims 13
- 125000004076 pyridyl group Chemical group 0.000 claims 13
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 12
- 229910052794 bromium Inorganic materials 0.000 claims 12
- 229910052801 chlorine Inorganic materials 0.000 claims 12
- 239000000460 chlorine Substances 0.000 claims 12
- 229910052731 fluorine Inorganic materials 0.000 claims 12
- 239000011737 fluorine Substances 0.000 claims 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000002757 morpholinyl group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 11
- 125000004191 (C1-C6) alkoxy group Chemical class 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 9
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 9
- 125000000168 pyrrolyl group Chemical group 0.000 claims 9
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000005493 quinolyl group Chemical group 0.000 claims 3
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 101710138860 Hypoxia-inducible factor prolyl hydroxylase Proteins 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000000466 oxiranyl group Chemical group 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410442574.4 | 2014-09-02 | ||
| CN201410442574 | 2014-09-02 | ||
| PCT/CN2015/088799 WO2016034108A1 (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525737A JP2017525737A (ja) | 2017-09-07 |
| JP2017525737A5 true JP2017525737A5 (enExample) | 2018-06-14 |
| JP6506390B2 JP6506390B2 (ja) | 2019-04-24 |
Family
ID=55417512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512046A Active JP6506390B2 (ja) | 2014-09-02 | 2015-09-01 | キノリノン系化合物及びその薬物への使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10065928B2 (enExample) |
| EP (1) | EP3190104B1 (enExample) |
| JP (1) | JP6506390B2 (enExample) |
| CN (1) | CN105384687B (enExample) |
| AU (1) | AU2015311333B2 (enExample) |
| CA (1) | CA2959688C (enExample) |
| ES (1) | ES2898476T3 (enExample) |
| WO (1) | WO2016034108A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
| CN108069952B (zh) * | 2016-11-08 | 2022-09-27 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其在药物中应用 |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CN108285460A (zh) * | 2017-01-09 | 2018-07-17 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的药用盐及其制备方法与用途 |
| JP6999469B2 (ja) * | 2018-03-28 | 2022-01-18 | 東京応化工業株式会社 | 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子 |
| CN111269178A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269176A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| US20230002325A1 (en) * | 2019-11-28 | 2023-01-05 | Sunshine Lake Pharma Co., Ltd. | Crystal form of quinolinone compound and use thereof |
| CN111269177B (zh) * | 2019-11-28 | 2023-05-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型 |
| CN115010663A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| WO2022184159A1 (zh) * | 2021-03-05 | 2022-09-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010664A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN114989085B (zh) * | 2022-05-23 | 2023-11-24 | 安徽医科大学 | 一种芳基内酰胺环类化合物、药物组合物及其应用 |
| CN117159549B (zh) * | 2023-10-11 | 2025-02-14 | 中国药科大学 | 一种酯类化合物的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2357175A1 (en) | 2003-06-06 | 2011-08-17 | Fibrogen, Inc. | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN |
| EP1849465A4 (en) * | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| CN101166745A (zh) | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | 噻吩并吡啶化合物和其使用方法 |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| US7728130B2 (en) * | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
| CA2640435C (en) | 2006-01-27 | 2011-11-01 | Fibrogen, Inc. | Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| JP5111491B2 (ja) | 2006-04-04 | 2013-01-09 | フィブロジェン， インコーポレイテッド | ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法 |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| PE20080209A1 (es) | 2006-06-23 | 2008-05-15 | Smithkline Beecham Corp | Derivados de glicina como inhibidores de prolil hidroxilasa |
| IL196127A (en) | 2006-06-26 | 2013-12-31 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors, pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them and uses thereof for the treatment of a variety of diseases |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| CA2672656C (en) | 2006-12-18 | 2012-03-20 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| EP2097416B1 (en) | 2006-12-18 | 2012-09-12 | Amgen, Inc | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| CA2683738C (en) | 2007-04-18 | 2012-03-20 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| WO2008130600A2 (en) | 2007-04-18 | 2008-10-30 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| CN101663037A (zh) * | 2007-04-18 | 2010-03-03 | 默克公司 | 新的1,8-二氮杂萘化合物 |
| AU2008248234B2 (en) | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| KR20100045480A (ko) | 2007-08-10 | 2010-05-03 | 크리스탈지노믹스(주) | 피리딘 유도체 및 이들의 사용방법 |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039322A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JP2011505367A (ja) | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| CN101983384A (zh) | 2007-11-30 | 2011-03-02 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
| EP2227475B1 (en) | 2007-12-03 | 2014-02-19 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| US20100298324A1 (en) | 2007-12-19 | 2010-11-25 | Smith Kline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| CN101951776A (zh) | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢-1h-吡咯稠合吡啶酮 |
| CA2712583A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrothieno pyridines |
| WO2009108496A1 (en) | 2008-02-25 | 2009-09-03 | Merck & Co., Inc. | Tetrahydrofuropyridones |
| BRPI0911444B8 (pt) | 2008-04-28 | 2021-05-25 | Janssen Pharmaceutica Nv | benzoimidazóis como inibidores de prolil hidroxilase e composição farmacêutica que os compreende |
| WO2009134847A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JP2011519858A (ja) | 2008-04-30 | 2011-07-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラ−ゼ阻害剤 |
| US20110098324A1 (en) | 2008-06-25 | 2011-04-28 | Brackley Iii James A | Prolyl hydroxylase inhibitors |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| EP2326178A4 (en) | 2008-08-21 | 2012-10-24 | Glaxosmithkline Llc | INHIBITORS OF PROLYL-HYDROXYLASE |
| WO2010025087A1 (en) | 2008-08-25 | 2010-03-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| CN105037323A (zh) | 2008-11-14 | 2015-11-11 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| RU2528412C2 (ru) | 2009-02-10 | 2014-09-20 | Янссен Фармацевтика Нв | Хиназолиноны как ингибиторы пролилгидроксилазы |
| WO2011006355A1 (en) | 2009-07-15 | 2011-01-20 | Beijing Beta Pharma Inc. | Compounds as hypoxia mimetics, and compositions, and uses thereof |
| SG178049A1 (en) | 2009-07-17 | 2012-03-29 | Japan Tobacco Inc | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| TWI500623B (zh) | 2009-10-13 | 2015-09-21 | Torrent Pharmaceuticals Ltd | 新穎稠合噻唑及噁唑嘧啶酮 |
| WO2011056725A1 (en) | 2009-11-05 | 2011-05-12 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| US8541430B2 (en) | 2009-11-27 | 2013-09-24 | Torrent Pharmaceuticals Limited | Fused thiazolo and oxazolo pyrimidinones |
| WO2012021830A1 (en) | 2010-08-13 | 2012-02-16 | Janssen Pharmaceutica Nv | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
| US8921389B2 (en) | 2011-02-02 | 2014-12-30 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| WO2012170439A1 (en) | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| CA2843240A1 (en) | 2011-07-29 | 2013-02-07 | Beijing Betta Pharmaceuticals Co., Ltd | Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof |
| JP6129217B2 (ja) | 2012-03-09 | 2017-05-17 | フィブロジェン インコーポレイテッド | Ｈｉｆヒドロキシラーゼインヒビターとしての４−ヒドロキシ−イソキノリン化合物 |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| WO2014014834A1 (en) | 2012-07-16 | 2014-01-23 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| TWI583670B (zh) | 2012-07-30 | 2017-05-21 | 大正製藥股份有限公司 | Partially saturated nitrogenous heterocyclic compounds |
| US20150239889A1 (en) | 2012-08-23 | 2015-08-27 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compound |
| US9394300B2 (en) * | 2012-12-24 | 2016-07-19 | Cadila Healthcare Limited | Quinolone derivatives |
| CA2899024C (en) | 2013-01-24 | 2022-01-04 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
-
2015
- 2015-09-01 US US15/502,499 patent/US10065928B2/en active Active
- 2015-09-01 CN CN201510557206.9A patent/CN105384687B/zh active Active
- 2015-09-01 EP EP15837609.5A patent/EP3190104B1/en active Active
- 2015-09-01 AU AU2015311333A patent/AU2015311333B2/en active Active
- 2015-09-01 WO PCT/CN2015/088799 patent/WO2016034108A1/zh not_active Ceased
- 2015-09-01 ES ES15837609T patent/ES2898476T3/es active Active
- 2015-09-01 CA CA2959688A patent/CA2959688C/en active Active
- 2015-09-01 JP JP2017512046A patent/JP6506390B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525737A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2010532387A5 (enExample) | ||
| JP2017527561A5 (enExample) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| JP2015522650A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2018514544A5 (enExample) | ||
| JP2016505512A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2017515901A5 (enExample) | ||
| AR092045A1 (es) | Combinaciones farmaceuticas | |
| JP2020529994A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| RU2012158142A (ru) | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации | |
| JP2019531279A5 (enExample) | ||
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2015521195A5 (enExample) | ||
| JP2017516796A5 (enExample) |